GeoVax.png
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
March 06, 2024 09:00 ET | GeoVax, Inc.
Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines ATLANTA, GA, March 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc....
July 30, 2021 - ROSEN LOGO.jpg
BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action – BNTX
February 27, 2024 19:49 ET | The Rosen Law Firm PA
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and...
logo.png
Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19
February 21, 2024 08:00 ET | BIOXYTRAN, INC.
First Medicinal chemistry of an antiviral drug made of sugars BOSTON, MASSACHUSETTS, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT), (the “Company”), a clinical stage biotechnology...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages BioVie Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BIVI
February 09, 2024 19:45 ET | The Rosen Law Firm PA
NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioVie Inc. (NASDAQ: BIVI) between August 5, 2021 and...
AIM ImmunoTech Inc.
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
February 08, 2024 08:50 ET | AIM ImmunoTech Inc.
Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions Safety results show Ampligen is generally well tolerated in the treatment of...
invivyd-logo.jpg
Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 05, 2024 16:02 ET | Invivyd
WALTHAM, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today...
MetrioPharm Publishes First Trial Data Showing Effects of Host-Directed Therapy in COVID-19
January 31, 2024 05:00 ET | AKAMPION
Results of clinical trial CT-05 in 131 hospitalized patients with COVID-19Trial data demonstrate that MetrioPharm´s lead compound MP1032 has comparable efficacy to remdesivir with several additional...
MetrioPharm veröffentlicht Studiendaten, die die Wirkung einer Host-Directed Therapy in COVID-19 zeigen
January 31, 2024 05:00 ET | AKAMPION
Ergebnisse stammen aus der klinischen Studie CT-05 an 131 hospitalisierten Patienten mit COVID-19Die Daten zeigen, dass MetrioPharms Leitsubstanz MP1032 eine mit Remdesivir vergleichbare Wirksamkeit...
InflaRx on large white.jpg
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
January 25, 2024 07:30 ET | InflaRx N.V.
InflaRx to cover costs of GOHIBIC for patients who are treated in line with its Emergency Use Authorization (EUA) but do not survive. InflaRx is determined to support broader access to GOHIBIC for...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages BioVie Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BIVI
January 23, 2024 11:14 ET | The Rosen Law Firm PA
NEW YORK, Jan. 23, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of BioVie...